Exagen, Inc. (XGN)
7.41
-0.02
(-0.27%)
USD |
NASDAQ |
Oct 20, 16:00
7.35
-0.06
(-0.81%)
Pre-Market: 08:02
Exagen Research and Development Expense (TTM) : 6.466M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.466M |
| March 31, 2026 | 6.523M |
| December 31, 2025 | 6.254M |
| September 30, 2025 | 6.153M |
| June 30, 2025 | 5.904M |
| March 31, 2025 | 5.60M |
| December 31, 2024 | 5.375M |
| September 30, 2024 | 4.795M |
| June 30, 2024 | 4.714M |
| March 31, 2024 | 4.798M |
| December 31, 2023 | 4.865M |
| September 30, 2023 | 6.49M |
| June 30, 2023 | 7.472M |
| March 31, 2023 | 8.898M |
| December 31, 2022 | 9.876M |
| September 30, 2022 | 9.377M |
| June 30, 2022 | 8.735M |
| March 31, 2022 | 7.938M |
| December 31, 2021 | 7.237M |
| September 30, 2021 | 6.20M |
| June 30, 2021 | 5.478M |
| March 31, 2021 | 4.337M |
| Date | Value |
|---|---|
| December 31, 2020 | 3.568M |
| September 30, 2020 | 2.969M |
| June 30, 2020 | 2.458M |
| March 31, 2020 | 2.297M |
| December 31, 2019 | 2.176M |
| September 30, 2019 | 2.143M |
| June 30, 2019 | 2.161M |
| March 31, 2019 | 2.116M |
| December 31, 2018 | 2.125M |
| September 30, 2018 | 2.009M |
| June 30, 2018 | 1.795M |
| March 31, 2018 | 1.596M |
| December 31, 2015 | 1.367M |
| September 30, 2015 | 1.297M |
| June 30, 2015 | 1.316M |
| March 31, 2015 | 1.34M |
| December 31, 2014 | 1.287M |
| September 30, 2014 | 1.17M |
| June 30, 2014 | 1.05M |
| March 31, 2014 | 0.906M |
| December 31, 2013 | 0.897M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Myriad Genetics, Inc. | 105.80M |
| BioRestorative Therapies, Inc. | 9.374M |
| CareDx, Inc. | 79.87M |
| Natera, Inc. | 787.38M |
| Sera Prognostics, Inc. | 12.27M |